These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 32695118)

  • 1. Delicate Balances in Cancer Chemotherapy: Modeling Immune Recruitment and Emergence of Systemic Drug Resistance.
    Tran AP; Ali Al-Radhawi M; Kareva I; Wu J; Waxman DJ; Sontag ED
    Front Immunol; 2020; 11():1376. PubMed ID: 32695118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metronomic cyclophosphamide schedule-dependence of innate immune cell recruitment and tumor regression in an implanted glioma model.
    Wu J; Waxman DJ
    Cancer Lett; 2014 Oct; 353(2):272-80. PubMed ID: 25069038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metronomic cyclophosphamide activation of anti-tumor immunity: tumor model, mouse host, and drug schedule dependence of gene responses and their upstream regulators.
    Wu J; Jordan M; Waxman DJ
    BMC Cancer; 2016 Aug; 16():623. PubMed ID: 27515027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transcriptional profiling provides insights into metronomic cyclophosphamide-activated, innate immune-dependent regression of brain tumor xenografts.
    Doloff JC; Waxman DJ
    BMC Cancer; 2015 May; 15():375. PubMed ID: 25952672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CpG-1826 immunotherapy potentiates chemotherapeutic and anti-tumor immune responses to metronomic cyclophosphamide in a preclinical glioma model.
    Jordan M; Waxman DJ
    Cancer Lett; 2016 Apr; 373(1):88-96. PubMed ID: 26655275
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medium dose intermittent cyclophosphamide induces immunogenic cell death and cancer cell autonomous type I interferon production in glioma models.
    Du B; Waxman DJ
    Cancer Lett; 2020 Feb; 470():170-180. PubMed ID: 31765733
    [TBL] [Abstract][Full Text] [Related]  

  • 7. VEGF receptor inhibitors block the ability of metronomically dosed cyclophosphamide to activate innate immunity-induced tumor regression.
    Doloff JC; Waxman DJ
    Cancer Res; 2012 Mar; 72(5):1103-15. PubMed ID: 22237627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intermittent metronomic drug schedule is essential for activating antitumor innate immunity and tumor xenograft regression.
    Chen CS; Doloff JC; Waxman DJ
    Neoplasia; 2014 Jan; 16(1):84-96. PubMed ID: 24563621
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metronomic treatment in immunocompetent preclinical GL261 glioblastoma: effects of cyclophosphamide and temozolomide.
    Ferrer-Font L; Arias-Ramos N; Lope-Piedrafita S; Julià-Sapé M; Pumarola M; Arús C; Candiota AP
    NMR Biomed; 2017 Sep; 30(9):. PubMed ID: 28570014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-tumor innate immunity activated by intermittent metronomic cyclophosphamide treatment of 9L brain tumor xenografts is preserved by anti-angiogenic drugs that spare VEGF receptor 2.
    Doloff JC; Chen CS; Waxman DJ
    Mol Cancer; 2014 Jun; 13():158. PubMed ID: 24965046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical analysis of resistance and cross-resistance to low-dose metronomic chemotherapy.
    Chow A; Wong A; Francia G; Man S; Kerbel RS; Emmenegger U
    Invest New Drugs; 2014 Feb; 32(1):47-59. PubMed ID: 23728939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metronomic cyclophosphamide eradicates large implanted GL261 gliomas by activating antitumor Cd8
    Wu J; Waxman DJ
    Oncoimmunology; 2015 Apr; 4(4):e1005521. PubMed ID: 26137402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors.
    Folkins C; Man S; Xu P; Shaked Y; Hicklin DJ; Kerbel RS
    Cancer Res; 2007 Apr; 67(8):3560-4. PubMed ID: 17440065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repeated tumor oximetry to identify therapeutic window during metronomic cyclophosphamide treatment of 9L gliomas.
    Mupparaju S; Hou H; Lariviere JP; Swartz H; Jounaidi Y; Khan N
    Oncol Rep; 2011 Jul; 26(1):281-6. PubMed ID: 21503586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Type-I interferon signaling is essential for robust metronomic chemo-immunogenic tumor regression in murine breast cancer.
    Vergato C; Doshi KA; Roblyer D; Waxman DJ
    Cancer Res Commun; 2022 Apr; 2(4):246-257. PubMed ID: 36187936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy.
    Munoz R; Man S; Shaked Y; Lee CR; Wong J; Francia G; Kerbel RS
    Cancer Res; 2006 Apr; 66(7):3386-91. PubMed ID: 16585158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The potential clinical promise of 'multimodality' metronomic chemotherapy revealed by preclinical studies of metastatic disease.
    Kerbel RS; Shaked Y
    Cancer Lett; 2017 Aug; 400():293-304. PubMed ID: 28202353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pigment epithelium-derived factor expression prolongs survival and enhances the cytotoxicity of low-dose chemotherapy in castration-refractory prostate cancer.
    Nelius T; Martinez-Marin D; Hirsch J; Miller B; Rinard K; Lopez J; de Riese W; Filleur S
    Cell Death Dis; 2014 May; 5(5):e1210. PubMed ID: 24810046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of metronomic UFT/cyclophosphamide chemotherapy and antiangiogenic drug assessed in a new preclinical model of locally advanced orthotopic hepatocellular carcinoma.
    Tang TC; Man S; Lee CR; Xu P; Kerbel RS
    Neoplasia; 2010 Mar; 12(3):264-74. PubMed ID: 20234820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of acquired resistance to metronomic oral topotecan chemotherapy plus pazopanib after prolonged preclinical potent responsiveness in advanced ovarian cancer.
    Cruz-Muñoz W; Di Desidero T; Man S; Xu P; Jaramillo ML; Hashimoto K; Collins C; Banville M; O'Connor-McCourt MD; Kerbel RS
    Angiogenesis; 2014 Jul; 17(3):661-73. PubMed ID: 24569856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.